number of access : ?
number of downloads : ?
ID 115290
Author
Bando, Hiroshi Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN Search Researchers
Keywords
Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) study
Canagliflozin cardioVascular Assessment Study (CANVAS)
Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study
The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study
sodium–glucose cotransporter 2 (SGLT2) inhibitors
Content Type
Journal Article
Description
Patients with diabetes and heart failure have been increasing due to Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) study. β-blockers showed significantly suppressed cardiovascular events in the strict glycemic control group. Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) seem to be beneficial for diabetes and heart failure. Clinical efficacy of β-blockers would be suggested from three studies including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial, Canagliflozin cardioVascular Assessment Study (CANVAS) and Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study. Further discussion will be expected with research in detail.
Journal Title
Endocrinology & Metabolism International Journal
ISSN
24730815
Publisher
MedCrave Publishing
Volume
8
Issue
4
Start Page
97
End Page
99
Published Date
2020-08-31
Rights
©2020 Bando. This is an open access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and build upon your work non-commercially.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences